Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Frederic Colombel

Showing results (241-250 of 462) with videos related to

Pageof 47
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 17, 2019
Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse OutcomesRyan C Ungaro, Berkeley N Limketkai, Camilla Bjørn Jensen, et al.
Journal of Crohn'S & Colitis|April 22, 2021
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical TrialsJulian Panés, Séverine Vermeire, Marla C Dubinsky, et al.
Journal of Crohn'S & Colitis|July 12, 2025
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpointJean-Frederic Colombel, Jianmin Wu, Taku Kobayashi, et al.
Gastroenterology|December 24, 2013
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's diseaseMark T Osterman, William J Sandborn, Jean-Frederic Colombel, et al.
Digestive Diseases and Sciences|January 1, 2021
Increasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBDAdam S Faye, Timothy Wen, Ali Soroush, et al.
Inflammatory Bowel Diseases|July 17, 2024
Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple SclerosisMiguel Regueiro, Britta Siegmund, Sara Horst, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 1, 2024
Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease ProgressionNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Medrxiv : the Preprint Server for Health Sciences|January 27, 2021
Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patientsJohn Sperger, Kushal S Shah, Minxin Lu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2020
Recycling of Precolectomy Anti-Tumor Necrosis Factor Agents in Chronic Pouch Inflammation Is Associated With Treatment FailureMaia Kayal, Thomas Lambin, Michael Plietz, et al.
Human Pathology|March 21, 2018
Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's diseaseXiaofei Zhang, Huaibin Mabel Ko, Joana Torres, et al.
Pageof 47

Showing results (241-250 of 462) with videos related to

Sort By:
Pageof 47
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 17, 2019
Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse OutcomesRyan C Ungaro, Berkeley N Limketkai, Camilla Bjørn Jensen, et al.
Journal of Crohn'S & Colitis|April 22, 2021
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical TrialsJulian Panés, Séverine Vermeire, Marla C Dubinsky, et al.
Journal of Crohn'S & Colitis|July 12, 2025
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpointJean-Frederic Colombel, Jianmin Wu, Taku Kobayashi, et al.
Gastroenterology|December 24, 2013
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's diseaseMark T Osterman, William J Sandborn, Jean-Frederic Colombel, et al.
Digestive Diseases and Sciences|January 1, 2021
Increasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBDAdam S Faye, Timothy Wen, Ali Soroush, et al.
Inflammatory Bowel Diseases|July 17, 2024
Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple SclerosisMiguel Regueiro, Britta Siegmund, Sara Horst, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 1, 2024
Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease ProgressionNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Medrxiv : the Preprint Server for Health Sciences|January 27, 2021
Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patientsJohn Sperger, Kushal S Shah, Minxin Lu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2020
Recycling of Precolectomy Anti-Tumor Necrosis Factor Agents in Chronic Pouch Inflammation Is Associated With Treatment FailureMaia Kayal, Thomas Lambin, Michael Plietz, et al.
Human Pathology|March 21, 2018
Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's diseaseXiaofei Zhang, Huaibin Mabel Ko, Joana Torres, et al.
Pageof 47